Next Article in Journal
Breast Cancer Cell–Neutrophil Interactions Enhance Neutrophil Survival and Pro-Tumorigenic Activities
Next Article in Special Issue
Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs
Previous Article in Journal
Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer
Open AccessEditorial

Novel Treatment Strategies for Glioblastoma

Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia
Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia
Cancers 2020, 12(10), 2883;
Received: 22 September 2020 / Accepted: 6 October 2020 / Published: 8 October 2020
(This article belongs to the Special Issue Novel Treatment Strategies for Glioblastoma)
Glioblastoma (GBM) is the most common primary central nervous system tumor in adults. It is a highly invasive disease, making it difficult to achieve a complete surgical resection, resulting in poor prognosis with a median survival of 12–15 months after diagnosis, and less than 5% of patients survive more than 5 years. Surgical, instrument technology, diagnostic and radio/chemotherapeutic strategies have slowly evolved over time, but this has not translated into significant increases in patient survival. The current standard of care for GBM patients involving surgery, radiotherapy, and concomitant chemotherapy temozolomide (known as the Stupp protocol), has only provided a modest increase of 2.5 months in median survival, since the landmark publication in 2005. There has been considerable effort in recent years to increase our knowledge of the molecular landscape of GBM through advances in technology such as next-generation sequencing, which has led to the stratification of the disease into several genetic subtypes. Current treatments are far from satisfactory, and studies investigating acquired/inherent resistance to current therapies, restricted drug delivery, inter/intra-tumoral heterogeneity, drug repurposing and a tumor immune-evasive environment have been the focus of intense research over recent years. While the clinical advancement of GBM therapeutics has seen limited progression compared to other cancers, developments in novel treatment strategies that are being investigated are displaying encouraging signs for combating this disease. This aim of this editorial is to provide a brief overview of a select number of these novel therapeutic approaches. View Full-Text
Keywords: glioblastoma; glioma; temozolomide; radiotherapy; immunotherapy; novel therapy; personalized treatment; drug repurposing glioblastoma; glioma; temozolomide; radiotherapy; immunotherapy; novel therapy; personalized treatment; drug repurposing
MDPI and ACS Style

Stylli, S.S. Novel Treatment Strategies for Glioblastoma. Cancers 2020, 12, 2883.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop